Ovid Therapeutics announces CEO succession, Q3 2025 loss, and pipeline progress

Ovid Therapeutics Inc.

Meg Alexander appointed CEO effective Jan 1, 2026; Jeremy Levin to become Executive Chairman.
Q3 2025 net loss $12.2M ($0.17/sh) vs $14.0M ($0.20) YoY; cash $25.6M at Sep 30.
Completed $81M private placement (up to $175M); cash runway extended into 2H 2028.
OV329 Phase 1 positive; Phase 2a in drug-resistant epilepsies planned Q2 2026.
OV350 IV data expected Q4 2025; OV4071 oral KCC2 activator to enter clinic Q2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.